Controlled Release Drug Delivery Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 5.60 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Controlled Release Drug Delivery Market Analysis
The Controlled Release Drug Delivery Market is expected to register a CAGR of 5.60% during the forecast period.
The rising prevalence of chronic diseases is anticipated to boost the demand for controlled-release drug delivery technology as it maximizes the efficacy of the therapeutic and minimizes the side effects, which adds to the market's growth.
The rising incidence of chronic diseases is expected to boost the demand for controlled-release drug delivery technology. This technology offers several advantages, including improved patient compliance, reduced dosing frequency, and enhanced therapeutic efficacy. Chronic diseases such as diabetes, cardiovascular diseases, and cancer continue to increase, and the need for advanced drug delivery systems becomes more critical. Consequently, the controlled-release drug delivery technology market is anticipated to grow during the forecast period. For instance, according to the data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2023, an estimated 279,260 new cases of cancer were expected to occur in Spain by the end of 2023, out of which 42,721 new cases of colorectal cancer, 31,282 cases of lung cancer, and 21,694 cases of urinary bladder cancer were expected to occur in Spain in 2023. Thus, the high burden of chronic diseases that require control release formulation to the target cell is anticipated to boost the market's growth during the forecast period.
Additionally, according to June 2024 statistics published by the Australian Institutes of Health and Welfare, there were 53,000 hospitalizations with a principal diagnosis of COPD for people aged 45 and above (500 hospitalizations per 100,000 population) in 2022. Additionally, according to the December 2023 article published by Jama Network, by 2050, the global prevalence of COPD is forecasted to reach nearly 600 million cases, indicating a 23% increase from the 2020 figures. The high burden of COPD worldwide boosts the demand for controlled-release drugs that can be used in various types of inhalers, which are projected to augment the market's growth during the forecast period.
Furthermore, the strategic initiatives by market players for innovation and launches in existing products also contribute significantly to market growth. For instance, in February 2022, AstraZeneca launched the Ambition Zero Carbon Program in partnership with Honeywell to develop next-generation respiratory inhalers. Under the partnership, the companies will eliminate the propellent that was earlier used in metered dose inhalers for patients with asthma and COPD. Therefore, the partnership will boost the development of advanced metered dose inhalers, which is further projected to accelerate the market's growth during the forecast period.
Therefore, factors such as the rising prevalence of chronic disease and increasing strategic initiatives by market players are expected to drive the market's growth during the forecast period. However, the higher cost compared to the conventional method is expected to restrain the market's growth during the forecast period.
Controlled Release Drug Delivery Market Trends
The Targeted Delivery Segment is Expected to Hold a Major Market Share in the Market
The targeted delivery segment is poised for growth, driven by the rising demand for targeted drug delivery during the forecast period. This surge is further fueled by the expanding geriatric and pediatric populations. Unlike traditional systems, targeted delivery systems offer a prolonged therapeutic effect, ensuring drugs are released at a predetermined rate directly at the target site.
Targeted drug delivery is effective in various chronic diseases, such as cancer, genetic diseases, and chronic illnesses, and it delivers the drug at the targeted site by facilitating precise and cell-specific drug delivery. For instance, according to the article published in Pharmacological Research in March 2024, nanocarriers can selectively release chemotherapy drugs at tumor sites, reducing harm to healthy tissues in cancer treatment. This targeted approach enhances drug effectiveness and minimizes side effects. Notable examples include Imatinib (Gleevec), a groundbreaking drug in treating chronic myeloid leukemia (CML).
Moreover, key manufacturers are ramping up research and development efforts to cater to the surging demand for innovative targeted drug delivery products, propelling the segment's growth. For instance, in March 2022, AstraZeneca unveiled its initiative to craft advanced drug delivery systems. These systems aim for the targeted and controlled release of novel molecules, ensuring they maximize their therapeutic benefits for patients. Given these developments, the segment is poised to command a significant share of the market during the forecast period.
Thus, the growing application of targeted drug delivery in chronic diseases and strategic activities by the market players is expected to contribute to the segment's growth.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is expected to hold a substantial share of the controlled-release drug delivery market owing to a surge in chronic diseases, such as cancer and HIV, and a rise in product launches. The growing burden of several chronic diseases in the region is expected to increase the demand for control release formulation for targeted delivery, thereby boosting the market's growth. For instance, according to the American Cancer Society Cancer Statistics 2024, 2 million new cancer cases are predicted to be diagnosed in the United States in 2024. The high burden of cancer creates an opportunity for market players to develop innovative drugs that boost the utilization of controlled-release drug delivery technologies, which is expected to expand the market's growth.
According to the article by the Canadian Cancer Society, in November 2023, 233.9 thousand people were predicted to be diagnosed with cancer in 2022. Therefore, the high burden of chronic diseases such as cancer and HIV is expected to boost the demand for controlled-release drug delivery devices for effective delivery and treatment, which is expected to accelerate the market's growth.
Research initiatives taken by market players to meet the demand for controlled-release drug delivery are also expected to boost the market's growth in this region. For instance, in June 2022, a research study was conducted at the University of Michigan that demonstrated a new method of drug microencapsulation, allowing several peptide drugs to be slowly released into the body. Such factors expand the utility of transdermal technology of controlled release drug delivery, accelerating the market's growth.
Therefore, owing to the rising burden of chronic diseases and launches by market players, the market is anticipated to boost in this region during the forecast period.
Controlled Release Drug Delivery Industry Overview
The controlled release drug delivery market is semi-consolidated and has several major players. A few of the major players are currently dominating the market in terms of market share. Some of the companies dominating the market are Adare Pharma Solutions, Merck and Co. Inc., Colorcon, Johnson and Johnson, Coating Place, Corium International Inc., GlaxoSmithKline, Bayer Healthcare LLC, and Lonza.
Controlled Release Drug Delivery Market Leaders
-
Adare Pharma Solutions
-
Merck KGaA
-
Johnson and Johnson
-
Lonza Group AG (Capsugel)
-
Colorcon
*Disclaimer: Major Players sorted in no particular order
Controlled Release Drug Delivery Market News
- January 2024: DelSiTech concluded a EUR 10 million financing round, marking its largest single funding achievement yet. This capital infusion is set to propel its innovative Silica-Based Drug Delivery Technology Platform. Bolstered by a promising internal pipeline, DelSiTech focuses on controlled-release drug products utilizing its Silica Matrix.
- January 2024: CD Formulation announced the launch of its dissolving microneedle preparation services. This breakthrough in drug delivery technology promises to revolutionize how medications are administered, enhancing efficiency and patient comfort. These microneedles comprise a biocompatible material that dissolves upon insertion, allowing for controlled and targeted drug release.
Controlled Release Drug Delivery Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Incidence of Chronic Diseases
4.2.2 Growing Geriatric and Pediatric Population
4.3 Market Restraints
4.3.1 Higher Cost Compared to the Conventional Method
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Technology
5.1.1 Micro Encapsulation
5.1.2 Transdermal
5.1.3 Targeted Delivery
5.1.4 Other Technologies
5.2 By Application
5.2.1 Metered Dose Inhalers
5.2.2 Injectable
5.2.3 Transdermal and Ocular Patches
5.2.4 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Adare Pharma Solutions
6.1.2 Merck and Co. Inc.
6.1.3 Colorcon
6.1.4 Johnson and Johnson
6.1.5 Coating Place
6.1.6 Corium International Inc.
6.1.7 GlaxoSmithKline PLC
6.1.8 Lonza
6.1.9 Bayer Healthcare LLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Controlled Release Drug Delivery Industry Segmentation
Controlled-release drug delivery is the dosage form that delivers a drug or medication in a predetermined manner. This drug delivery system provides continuous drug or medication delivery in predictable kinetics for the predetermined time in the whole course of gastrointestinal transit.
The controlled release drug delivery market is segmented by technology, application, and geography. By technology, the market is segmented into microencapsulation, transdermal, targeted delivery, and other technologies. By application, the market is segmented into metered dose inhalers, injectables, transdermal, ocular patches, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends of 17 countries across major regions globally.
The report offers values (in USD) for the above segments.
| By Technology | |
| Micro Encapsulation | |
| Transdermal | |
| Targeted Delivery | |
| Other Technologies |
| By Application | |
| Metered Dose Inhalers | |
| Injectable | |
| Transdermal and Ocular Patches | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Controlled Release Drug Delivery Market Research FAQs
What is the current Controlled Release Drug Delivery Market size?
The Controlled Release Drug Delivery Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)
Who are the key players in Controlled Release Drug Delivery Market?
Adare Pharma Solutions, Merck KGaA, Johnson and Johnson, Lonza Group AG (Capsugel) and Colorcon are the major companies operating in the Controlled Release Drug Delivery Market.
Which is the fastest growing region in Controlled Release Drug Delivery Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Controlled Release Drug Delivery Market?
In 2024, the North America accounts for the largest market share in Controlled Release Drug Delivery Market.
What years does this Controlled Release Drug Delivery Market cover?
The report covers the Controlled Release Drug Delivery Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Controlled Release Drug Delivery Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Controlled Release Drug Delivery Industry Report
Statistics for the 2024 Controlled Release Drug Delivery market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Controlled Release Drug Delivery analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
